- Home
- BAM vs SNY Comparison
BAM vs SNY Comparison
Compare BAM & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAM | SNY |
|---|---|---|
| Founded | 2022 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4B | 95.7B |
| IPO Year | 2022 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BAM | SNY |
|---|---|---|
| Price | $47.66 | $42.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 11 |
| Target Price | ★ $55.87 | $53.61 |
| AVG Volume (30 Days) | 2.9M | ★ 3.1M |
| Earning Date | 11-06-2026 | 10-30-2026 |
| Dividend Yield | 4.37% | ★ 5.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $4,817,000,000.00 | N/A |
| Revenue This Year | $27.67 | $1.46 |
| Revenue Next Year | $15.77 | $6.51 |
| P/E Ratio | $34.43 | ★ $6.14 |
| Revenue Growth | ★ 21.03 | N/A |
| 52 Week Low | $42.20 | $39.07 |
| 52 Week High | $56.37 | $52.68 |
Technical Indicators
Market Signals| Indicator | BAM | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 59.97 | 56.81 |
| Support Level | $46.77 | $41.19 |
| Resistance Level | $49.90 | $45.22 |
| Average True Range (ATR) | 1.19 | 0.70 |
| MACD | 0.38 | 0.32 |
| Stochastic Oscillator | 97.91 | 98.52 |
Price Performance
Historical ComparisonAbout BAM Brookfield Asset Management Inc Limited Voting Shares
Brookfield Asset Management is one of the world's largest alternative-asset managers, with USD 1.181 trillion in total managed assets, including USD 602.7 billion in fee-earning AUM, at the end of 2025. The company has three main business segments: credit strategies (USD 363.0 billion in total AUM and USD 279.4 billion in fee-earning AUM), private equity (USD 155.0 billion/USD 48.0 billion), and real estate/real assets (USD 663.0 billion/USD 275.3 billion). The firm primarily serves institutional investors (90% of AUM) and high-net-worth individuals (10%), and is diversified globally, with 67% of revenue from the Americas, 20% from EMEA, and 13% from Asia-Pacific. Canada-based Brookfield Corp. owns 73% of Brookfield's outstanding Class A shares.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.